Population Pharmacokinetics of Rituximab in Patients with Diffuse Large B-cell Lymphoma and Association with Clinical Outcome

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2017 Feb 28

PMID 28239897

Citations 26

Authors

Samo Rozman

Iztok Grabnar

Srdjan Novakovic

Ales Mrhar

Barbara Jezersek Novakovic

Affiliations

Soon will be listed here.

Abstract

Aims: Pharmacokinetic (PK) studies suggest that there is a room for improvement in clinical use of rituximab through more individualized treatment. The objective of this study was to characterize rituximab PK in 29 newly diagnosed patients with diffuse large B-cell lymphoma treated with rituximab in combination with cyclophosphamide, doxorubicin, vincristine and methylprednisolone every 3 weeks. We also evaluated the association of rituximab PK with clinical outcome.

Methods: Rituximab serum levels were determined by enzyme-linked immunosorbent assay and evaluated by a population PK analysis applying nonlinear mixed effects modelling.

Results: The data were best described by a two-compartment model comprising linear nonspecific clearance of 0.252 [95% confidence interval (CI): 0.227-0.279] l day and time-varying specific clearance of 0.278 (95% CI: 0.181-0.390) l day , corresponding to target-mediated drug disposition of rituximab. Nonspecific clearance was lower in older patients and those with lower body weight. Additionally, volume of the central compartment was higher in males. A clear association of clinical response with rituximab PK has been observed. Rate constant of specific clearance decay was 0.143 day (95% CI: 0.0478-0.418) in patients with no disease progression, while in patients with disease progression it was 82.2% lower (95% CI: 33.4-95.0).

Conclusions: This finding indicates that time-changes in clearance could serve as a predictive marker of response to rituximab. Our report demonstrates the rationale for studies evaluating higher doses of rituximab in selected patients.

Citing Articles

Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.

Moser M, Thalhammer R, Sillaber C, Derhaschnig U, Firbas C, Jager U Front Med (Lausanne). 2025; 11:1481333.

PMID: 39760040 PMC: 11695359. DOI: 10.3389/fmed.2024.1481333.

First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.

Yu H, Chen Y, Qi Y, Yang H, Cao G, Yang W CNS Neurosci Ther. 2024; 30(11):e70126.

PMID: 39592888 PMC: 11598743. DOI: 10.1111/cns.70126.

Clinical study design strategies to mitigate confounding effects of time-dependent clearance on dose optimization of therapeutic antibodies.

Proctor J, Wong H CPT Pharmacometrics Syst Pharmacol. 2024; 14(2):365-375.

PMID: 39575837 PMC: 11812930. DOI: 10.1002/psp4.13280.

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.

Li C, Bender B, Wilkins J, Li F, Turner D, Wang B Clin Pharmacol Ther. 2024; 117(2):465-474.

PMID: 39328022 PMC: 11739751. DOI: 10.1002/cpt.3445.

Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine.

Sutherland L, Carter L Heliyon. 2024; 10(12):e32597.

PMID: 39183838 PMC: 11341330. DOI: 10.1016/j.heliyon.2024.e32597.

References

Johnson P, Glennie M . The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003; 30(1 Suppl 2):3-8. DOI: 10.1053/sonc.2003.50025. View

Golay J, Semenzato G, Rambaldi A, Foa R, Gaidano G, Gamba E . Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013; 5(6):826-37. PMC: 3896596. DOI: 10.4161/mabs.26008. View

Ludden T, Beal S, Sheiner L . Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994; 22(5):431-45. DOI: 10.1007/BF02353864. View

Habermann T, Weller E, Morrison V, Gascoyne R, Cassileth P, Cohn J . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-7. DOI: 10.1200/JCO.2005.05.1003. View

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Blasco H, Chatelut E, de Bretagne I, Congy-Jolivet N, Le Guellec C . Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol. 2009; 23(5):601-8. DOI: 10.1111/j.1472-8206.2009.00714.x. View

Alexander S, Kelly E, Marrion N, Peters J, Benson H, Faccenda E . The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol. 2015; 172(24):5729-43. PMC: 4718217. DOI: 10.1111/bph.13347. View

Jazirehi A, Bonavida B . Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005; 24(13):2121-43. DOI: 10.1038/sj.onc.1208349. View

10.

Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N . Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014; 32(36):4127-33. DOI: 10.1200/JCO.2013.54.6861. View

11.

Plosker G, Figgitt D . Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63(8):803-43. DOI: 10.2165/00003495-200363080-00005. View

12.

Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T . Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012; 52(12):1918-26. DOI: 10.1177/0091270011430506. View

13.

Southan C, Sharman J, Benson H, Faccenda E, Pawson A, Alexander S . The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res. 2015; 44(D1):D1054-68. PMC: 4702778. DOI: 10.1093/nar/gkv1037. View

14.

Wang W, Wang E, Balthasar J . Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84(5):548-58. DOI: 10.1038/clpt.2008.170. View

15.

Pfreundschuh M, Muller C, Zeynalova S, Kuhnt E, Wiesen M, Held G . Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2013; 123(5):640-6. DOI: 10.1182/blood-2013-07-517037. View

16.

Ngo L, Hee S, Lim L, Tao M, Quek R, Yap S . Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. Leuk Lymphoma. 2008; 49(3):462-9. DOI: 10.1080/10428190701809156. View

17.

Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S . Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012; 97(9):1431-8. PMC: 3436246. DOI: 10.3324/haematol.2011.059246. View

18.

Cartron G, Watier H, Golay J, Solal-Celigny P . From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004; 104(9):2635-42. DOI: 10.1182/blood-2004-03-1110. View

19.

Berinstein N, Grillo-Lopez A, White C, Bence-Bruckler I, Maloney D, Czuczman M . Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998; 9(9):995-1001. DOI: 10.1023/A:1008416911099. View

20.

Molina A . A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008; 59:237-50. DOI: 10.1146/annurev.med.59.060906.220345. View